help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on December 18, 2003
Endocrinology, doi:10.1210/en.2003-1369
A more recent version of this article appeared on April 1, 2004
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
145/4/1842    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hewitt, K. N.
Right arrow Articles by Simpson, E. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hewitt, K. N.
Right arrow Articles by Simpson, E. R.

Submitted on October 14, 2003
Accepted on December 8, 2003

Estrogen replacement reverses the hepatic steatosis phenotype in the male aromatase knockout (ArKO) mouse

Kylie N. Hewitt1*, Kyriakos Pratis1, Margaret E.E. Jones1, and Evan R. Simpson1

1 Prince Henry's Institute of Medical Research, P.O. Box 5152, Clayton, Vic 3168, Australia and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria 3800, Australia.

* To whom correspondence should be addressed. E-mail: Kylie.Hewitt{at}phimr.monash.edu.au.

The aromatase knockout (ArKO) mouse cannot synthesize endogenous estrogens due to a disruption to the Cyp19 gene. Previously, we have shown both male and female ArKO mice have an age progressive obese phenotype, and a sexually dimorphic disruption to hepatic cholesterol and triglyceride homeostasis. Only ArKO males have elevated hepatic triglyceride levels leading to hepatic steatosis partly due to an increase in expression of enzymes involved in de novo lipogenesis and transporters involved in fatty acid uptake. In this study ArKO males were treated with 17{beta}-estradiol (3 µg/ kg/ day) at 18 weeks old for 6 weeks. WT controls were not treated and ArKO controls received vehicle oil injections. Estrogen replacement reverses the previously reported obese and fatty liver phenotypes; this was achieved by reductions in gonadal, visceral and brown adipose tissue weights and significantly decreased hepatic triglyceride levels. Estrogen deficiency led to a significant up-regulation of hepatic fatty acid synthase expression which was reduced with 17{beta}-estradiol replacement, although not quite reaching significance. Acetyl CoA carboxylase {alpha} mRNA expression showed no significant changes. Expression of transcripts encoding adipocyte differentiated regulatory protein, a fatty acid transporter, was significantly elevated in estrogen deficient males and 17{beta}-estradiol replacement significantly reduced these levels. Scavenger receptor class b type 1 showed no significantly changes. This study reveals that the previously reported disruption to triglyceride homeostasis in estrogen deficient males can be reversed with 17{beta}-estradiol treatment, indicating an important role for estrogen in maintaining triglyceride and fatty acid homeostasis in males.


Key words: estrogen • aromatase • hepatic steatosis • triglycerides




This article has been cited by other articles:


Home page
EndocrinologyHome page
M. Penza, C. Montani, A. Romani, P. Vignolini, B. Pampaloni, A. Tanini, M. L. Brandi, P. Alonso-Magdalena, A. Nadal, L. Ottobrini, et al.
Genistein Affects Adipose Tissue Deposition in a Dose-Dependent and Gender-Specific Manner
Endocrinology, December 1, 2006; 147(12): 5740 - 5751.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
F. Magkos, B. W. Patterson, and B. Mittendorfer
No effect of menstrual cycle phase on basal very-low-density lipoprotein triglyceride and apolipoprotein B-100 kinetics
Am J Physiol Endocrinol Metab, December 1, 2006; 291(6): E1243 - E1249.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
M. Hamaguchi, T. Kojima, N. Takeda, T. Nakagawa, H. Taniguchi, K. Fujii, T. Omatsu, T. Nakajima, H. Sarui, M. Shimazaki, et al.
The Metabolic Syndrome as a Predictor of Nonalcoholic Fatty Liver Disease
Ann Intern Med, November 15, 2005; 143(10): 722 - 728.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
E. R. Simpson, M. Misso, K. N. Hewitt, R. A. Hill, W. C. Boon, M. E. Jones, A. Kovacic, J. Zhou, and C. D. Clyne
Estrogen--the Good, the Bad, and the Unexpected
Endocr. Rev., May 1, 2005; 26(3): 322 - 330.
[Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
P. S. Cooke and A. Naaz
Role of Estrogens in Adipocyte Development and Function
Experimental Biology and Medicine, December 1, 2004; 229(11): 1127 - 1135.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2003 by The Endocrine Society